home / stock / navb / navb news

NAVB News and Press, Navidea Biopharmaceuticals Inc. From 09/01/22

Stock Information
Company Name: Navidea Biopharmaceuticals Inc.
Stock Symbol: NAVB
Market: NYSE
Website: navidea.com
Menu
NAVB NAVB Quote NAVB Short NAVB News NAVB Articles NAVB Message Board
Get NAVB Alerts

News, Short Squeeze, Breakout and More Instantly...
NAVB - Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the opening of nine additional sites for recruitment into it...
NAVB - Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney's Fees

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on August 30, 2022, the District Court of Harris County...

NAVB -  Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update

Conference Call to be Held on Thursday, September 8, 2022 at 4:00 p.m. (EDT) Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today...

NAVB - Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the preliminary results of its rights offering which expired at 5:00 P.M. Eastern Time o...
NAVB - Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it has extended the initial rights offering subscriptio...

NAVB - Navidea Biopharm GAAP EPS of -$0.10, revenue of $0.06M

Navidea Biopharm press release ( NYSE: NAVB ): Q2 GAAP EPS of -$0.10. Revenue of $0.06M (-76.9% Y/Y). Navidea ended the second quarter of 2022 with $328,000 million in cash and cash equivalents. Shares +1.92% PM For further details see: Navidea Biopha...

NAVB - Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results

Conference Call to be Scheduled at a Later Date Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced ...
NAVB - Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the subscription period for the previously announced ri...

NAVB - Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the publication of a manuscript titled “Tilmanocept a...

NAVB - Navidea Biopharmaceuticals Reminds Investors of Today's Deadline to be a Shareholder of Record for the Previously Announced Rights Offering

To be a shareholder of record, investors are advised to own Navidea Biopharmaceuticals stock by 4:00 PM ET, Monday, August 1, 2022 to account for T+2 settlement timing Record date established as Wednesday, August 3, 2022 Navidea Biopharmaceuticals, Inc. (NYSE America...
Previous 10 Next 10